Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNMA1 | Q12791 | 13/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9792728 | 0.84 | KCNMA1 (0.60) | KCNMA1POLBMEN1KMT2AHPGD | |
| SCHEMBL14254815 | 0.84 | LMNA (0.62) | POLBMEN1KMT2AHPGDLMNA | |
| SCHEMBL4968141 | 0.84 | KCNMA1 (0.53) | KCNMA1POLBMEN1KMT2AHPGD | |
| SCHEMBL28295632 | 0.83 | KCNMA1 (0.68) | KCNMA1POLBMEN1KMT2AHPGD | |
| SCHEMBL7256022 | 0.83 | KCNMA1 (0.55) | KCNMA1POLBMEN1KMT2AHPGD | |
| SCHEMBL19910569 | 0.83 | LMNA (0.62) | POLBMEN1KMT2ALMNAMAPT | |
| SCHEMBL17845364 | 0.83 | ALDH1A1 (0.49) | MEN1KMT2ALMNATP53MAPT | |
| SCHEMBL7254163 | 0.81 | KCNMA1 (0.60) | KCNMA1POLBMEN1KMT2AHPGD | |
| SCHEMBL14254797 | 0.81 | ALDH1A1 (0.55) | MEN1KMT2AHPGDLMNANPC1 | |
| SCHEMBL14354719 | 0.81 | GAA (0.72) | KCNMA1POLBMEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7005439-B2 | Compounds | ASTRAZENECA AB (SE) | 2006-02-28 | — | — | US | disclosed |
| US-20050239801-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2005-10-27 | — | — | US | disclosed |
| EP-1299356-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-02-11 | — | — | EP | disclosed |
| CN-1447794-A | Novel compounds | ASTRAZENECA AB (SE) | 2003-10-08 | — | — | CN | disclosed |
| US-20030153555-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2003-08-14 | — | — | US | disclosed |
| EP-1299356-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2003-04-09 | — | — | EP | disclosed |
| WO-2001098272-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153555-A1 | Novel compounds | RPS4Y1, RPS4X, UGT2B7 | KCNMA1 2480/4885POLB 4533/4885MEN1 272/4885 |
| US-20050239801-A1 | Novel compounds | CHRM2, CHRM1, C1R | KCNMA1 1640/4885POLB 4323/4885MEN1 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.